Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Rhea-AI Summary

Precision BioSciences, Inc. (DTIL) will release financial results for Q4 and FY 2023 and give a business update on March 27, 2024.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320405180/en/

Investor and Media Contact:

Naresh Tanna

Vice President of Investor Relations

naresh.tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When will Precision BioSciences release financial results for the fourth quarter and fiscal year 2023?

Precision BioSciences will release financial results for the fourth quarter and fiscal year 2023 on March 27, 2024.

What is the ticker symbol for Precision BioSciences?

The ticker symbol for Precision BioSciences is DTIL.

What type of company is Precision BioSciences?

Precision BioSciences is an advanced gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies.